A Phase 1/2 interventional study of Injection of 68Ga-NI-FAPI in Tumor, Cardiovascular Diseases and Pulmonary Fibrosis, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Peking Union Medical College Hospital · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to conduct clinical research on [68Ga] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 30 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1: 18-85 years old
2: Tumor patients can undergo surgery or to obtain pathological diagnosis
3: Ability to understand and sign forms
4: Expected survival period exceeding 6 months and able to receive follow-up
5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc
Exclusion Criteria:
1: Pregnant or lactating women
2: Patients allergic to research drug ingredients
3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol/L)
4: Patients who participate in other clinical trials and interfere with the results of this study
5: Patients with severe illness who cannot cooperate with the examination
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Injection of \[68Ga\]Ga-NI-FAPI
Drug: Injection of 68Ga-NI-FAPI
Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight
Analysis of PET/CT Images of [68Ga] Ga-NI-FAPI-04
Semi quantitative analysis (measuring lesion standard uptake value (SUV), then calculating lesion SUV to liver/blood pool SUV ratio)
Time frame: Within 30-120 minutes after intravenous injection of imaging agent
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Feb 2027, 14 months after the start.
Of 102 non-industry phase 1/2 interventional studies under Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 111. This study's planned 14 months is below that.
Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital →